Lexicon Pharmaceuticals, Inc. (LXRX) Income Statement
LXRX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsLXRX revenue and net income
Where LXRX's revenue goes
2025Each bar shows an amount and its share of revenue. LXRX kept −101.1% of revenue as net income.
LXRX profit margins
LXRX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +60.2% | +610.3% | +15.7% | −9.1% |
| Gross profit | +62.6% | — | +17.6% | +3.6% |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
LXRX quarterly EPS vs estimates
Lexicon Pharmaceuticals beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.05).
LXRX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $49.8M | $31.1M | $1.2M | $139,000 | $298,000 | $24.0M | $322.1M | $63.2M | $90.3M | $83.3M |
| Cost of revenue | $274,000 | $616,000 | $59.0M | $52.5M | $55.0M | $1.9M | $3.2M | $2.5M | $1.9M | $164.0M |
| Gross profit | $49.5M | $30.5M | −$57.8M | −$52.4M | −$54.7M | $22.1M | $318.8M | $60.7M | $88.4M | −$80.6M |
| Research & development | $61.1M | $84.5M | $58.9M | $52.8M | $55.0M | $153.6M | $91.9M | $100.2M | $156.8M | $178.2M |
| Sales, general & admin | $37.3M | $143.1M | $97.7M | $48.1M | $32.3M | $47,230 | $56.8M | $63.8M | $66.2M | $43.0M |
| Total operating expenses | $98.4M | $227.6M | $114.0M | $48.4M | $32.3M | $69.9M | $177.4M | $164.0M | $223.0M | $221.2M |
| Operating income | −$48.9M | −$197.1M | −$171.8M | −$100.8M | −$87.1M | −$47.8M | $141.4M | −$103.3M | −$136.7M | −$137.2M |
| Interest income | $6.9M | $12.3M | $6.2M | $1.6M | $134,000 | $2.8M | $3.4M | $3.5M | $2.0M | $2.3M |
| Interest expense | $8.3M | $15.6M | $13.1M | $2.8M | $802,000 | $14.5M | $20.7M | $20.8M | $7.0M | $6.6M |
| Income before taxes | −$50.3M | −$200.4M | −$177.1M | −$101.9M | −$87.8M | −$58.6M | $124.1M | −$120.5M | −$141.7M | −$141.4M |
| Income taxes | — | −$200.4M | $386,105 | $1.2M | $510,000 | $11.6M | −$6.0M | $3.5M | −$12.7M | $4.5M |
| Net income | −$50.3M | −$200.4M | −$177.1M | −$101.9M | −$87.8M | −$58.6M | $130.1M | −$120.5M | −$129.1M | −$141.4M |
| EBITDA | −$41.4M | −$184.3M | −$169.8M | −$100.0M | −$86.7M | −$41.1M | $148.4M | −$96.1M | −$125.3M | −$125.8M |
| EPS (diluted) | −$0.14 | −$0.64 | −$0.80 | −$0.61 | −$0.61 | −$1.72 | $1.27 | −$1.15 | −$1.26 | −$1.37 |
| Gross margin | 99.4% | 98.0% | −4,798.0% | −37,681.3% | −18,371.8% | 92.0% | 99.0% | 96.1% | 97.9% | −96.8% |
| Operating margin | −98.2% | −634.2% | −14,265.0% | −72,489.2% | −29,224.8% | −199.2% | 43.9% | −163.4% | −151.3% | −164.6% |
| Net margin | −101.1% | −644.8% | −14,710.9% | −73,341.0% | −29,449.0% | −244.1% | 40.4% | −190.7% | −142.9% | −169.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $692,000 | $21.1M | $5.5M | $14.2M | $28.9M | $1.3M | $26.6M | $1.8M | $1.6M | $1.1M | $702,000 | $162,000 |
| Cost of revenue | $39,000 | $108,000 | $319,000 | $10,000 | $209,000 | $30,000 | $25.9M | $71,000 | $166,000 | $175,000 | $14.8M | $7,000 |
| Gross profit | $653,000 | $21.0M | $5.2M | $14.2M | $28.7M | $1.2M | $621,000 | $1.7M | $1.5M | $955,000 | −$14.1M | $155,000 |
| Research & development | $17.4M | $12.8M | $11.2M | $18.8M | $15.6M | $15.3M | $26.7M | $25.8M | $17.6M | $14.2M | $14.8M | $17.6M |
| Sales, general & admin | $9.8M | $9.2M | $8.8M | $7.6M | $9.3M | $11.6M | $32.3M | $39.6M | $39.2M | $32.1M | $34.8M | $32.2M |
| Total operating expenses | $27.2M | $22.0M | $20.0M | $26.4M | $24.9M | $26.9M | $33.4M | $65.4M | $56.8M | $46.3M | $32.6M | $49.8M |
| Operating income | −$26.5M | −$996,000 | −$14.8M | −$12.2M | $3.7M | −$25.7M | −$32.7M | −$63.7M | −$55.4M | −$45.3M | −$46.7M | −$49.6M |
| Interest income | $1.7M | $1.5M | $1.3M | $1.6M | $1.8M | $2.2M | $2.8M | $3.4M | $4.1M | $1.9M | $2.4M | $3.0M |
| Interest expense | $2.6M | $1.6M | $2.0M | $2.2M | $2.3M | $1.8M | $3.9M | $4.6M | $2.2M | $4.9M | $5.4M | $3.9M |
| Income before taxes | −$31.8M | −$1.0M | −$15.5M | −$12.8M | $3.3M | −$25.3M | −$33.8M | −$64.8M | −$53.4M | −$48.4M | −$49.8M | −$50.5M |
| Income taxes | — | — | — | — | — | — | −$101,000 | — | — | $100,724 | −$3.0M | $2.9M |
| Net income | −$31.8M | −$1.0M | −$15.5M | −$12.8M | $3.3M | −$25.3M | −$33.8M | −$64.8M | −$53.4M | −$48.4M | −$49.8M | −$50.5M |
| EBITDA | −$29.1M | $657,000 | −$13.4M | −$10.5M | $5.7M | −$23.3M | −$20.3M | −$60.1M | −$51.1M | −$44.5M | −$45.1M | −$46.5M |
| EPS (diluted) | −$0.06 | −$0.00 | −$0.04 | −$0.04 | $0.01 | −$0.07 | −$0.09 | −$0.18 | −$0.17 | −$0.20 | −$0.20 | −$0.21 |
| Gross margin | 94.4% | 99.5% | 94.2% | 99.9% | 99.3% | 97.6% | 2.3% | 95.9% | 89.9% | 84.5% | −2,012.8% | 95.7% |
| Operating margin | −3,835.3% | −4.7% | −269.1% | −85.9% | 12.9% | −2,034.8% | −123.3% | −3,639.6% | −3,360.9% | −4,011.8% | −6,657.7% | −30,636.4% |
| Net margin | −4,591.8% | −4.9% | −282.7% | −90.0% | 11.3% | −2,004.4% | −127.2% | −3,703.5% | −3,244.0% | −4,282.9% | −7,087.7% | −31,188.3% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in LXRX's financial statements (latest annual report filed March 5, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
LXRX financial results
In fiscal year 2025 (ended December 31, 2025), Lexicon Pharmaceuticals reported revenue of $49.8 million, up 60.2% from the year before. It had a net loss of $50.3 million, a net profit margin of −101.1%. Diluted earnings per share came to −$0.14. Over five years revenue grew at an average rate of 15.7% a year.
See the LXRX stock overview for the latest quote and news, or the LXRX chart for price history and technical indicators.
LXRX income statement FAQ
What is Lexicon Pharmaceuticals's annual revenue?
Lexicon Pharmaceuticals reported total revenue of $49.8 million for fiscal year 2025, which ended on December 31, 2025. That was up 60.2% from $31.1 million the previous year.
Is Lexicon Pharmaceuticals profitable?
No. Lexicon Pharmaceuticals reported a net loss of $50.3 million in fiscal 2025, a net profit margin of −101.1%; its operating margin was −98.2%.
What is Lexicon Pharmaceuticals's gross margin?
Lexicon Pharmaceuticals's gross margin was 99.4% in fiscal 2025: for every $100 of revenue, Lexicon Pharmaceuticals kept $99 after the direct cost of its products and services.
How much does Lexicon Pharmaceuticals spend on research and development?
Lexicon Pharmaceuticals spent $61.1 million on research and development in fiscal 2025, 122.7% of revenue.
How fast is Lexicon Pharmaceuticals growing?
Revenue grew 15.7% a year on average over the last five fiscal years, from $24.0 million to $49.8 million.
What are Lexicon Pharmaceuticals's earnings per share?
Lexicon Pharmaceuticals earned $-0.14 per diluted share in fiscal 2025, compared with $-0.64 a year earlier.
When will Lexicon Pharmaceuticals report its next earnings?
Lexicon Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens.
When does Lexicon Pharmaceuticals's fiscal year end?
Lexicon Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 5, 2026.